# Hpets

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hpets

- Industry: Biotechnology
- Headquarters: Chongqing, China
- Website: www.hanpets.cn/
- Latest round: Angel (Feb 26, 2024)
- Investors on record: 1

## About

Founded in 2022 and headquartered in Chongqing, China, Hpets Biotech (Chongqing) Co.,ltd operates as a pet medicine company committed to addressing unmet clinical needs in veterinary healthcare. The company provides innovative drug solutions for inflammatory, oncology, cardiovascular, and other common diseases in companion animals. In December 2025, Hpets raised CNY 10 million in venture funding.
Hpets specializes in the development and production of veterinary medicines, focusing on innovative therapeutic solutions for companion animals. Their core product offerings include active pharmaceutical ingredients (APIs) and intermediates specifically designed for a range of pet medications, as well as health supplements aimed at addressing significant unmet medical needs in pets. The company's products are formulated to enhance the health and well-being of animals, targeting conditions that are prevalent among companion species. The firm collaborates with commercial partners to develop new products and expand market reach, serving a diverse clientele including veterinary clinics and pet healthcare providers. Their geographical market encompasses both domestic and international sectors, ensuring that their products meet the evolving needs of pet owners and healthcare professionals globally.
The company generates revenue through direct sales of its pharmaceutical products and intermediates to veterinary clinics and distributors. The business operates primarily on a B2B model, establishing partnerships with wholesalers to effectively distribute its veterinary medicines and health supplements. Transactions typically involve bulk orders of their flagship products, which are priced competitively to reflect the high quality and efficacy of their formulations. The revenue structure may include contracts or agreements for ongoing supply, ensuring a steady stream of income from loyal clients who rely on their innovative solutions for animal health. The company’s commitment to quality and reliability positions it favorably within the biotechnology sector, fostering long-term relationships with customers in the veterinary field.

## Funding rounds

- Angel, Feb 26, 2024 — Liangjiang Capital

## Investors

- Liangjiang Capital — Angel